The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease
Open accessAbstract
The balance of intake of n-6 and n-3 PUFA, and consequently their relative incorporation into immune cells, is important in determining the development and severity of immune and inflammatory responses. Some disorders characterised by exaggerated inflammation and excessive formation of inflammatory markers have become among the most important causes of death and disability in man in modern societies. The recognition that long-chain n-3 PUFA have the potential to inhibit (excessive) inflammatory responses has led to a large number of clinical investigations with these fatty acids in inflammatory conditions as well as in healthy subjects. The present review explores the presence of dose-related effects of long-chain n-3 PUFA supplementation on immune markers and differences between healthy subjects and those with inflammatory conditions, because of the important implications for the transfer of information gained from studies with healthy subjects to patient populations, e.g. for establishing dose levels for specific applications. The effects of long-chain n-3 PUFA supplementation on ex vivo lymphocyte proliferation and cytokine production by lymphocytes and monocytes in healthy subjects have been studied in twenty-seven, twenty-five and forty-six treatment cohorts respectively, at intake levels ranging from 0·2 g EPA+DHA/d to 7·0 g EPA+DHA/d. Most studies, particularly those with the highest quality study design, have found no effects on these immune markers. Significant effects on lymphocyte proliferation are decreased responses in seven of eight cohorts, particularly in older subjects. The direction of the significant changes in cytokine production by lymphocytes is inconsistent and only found at supplementation levels ≥2·0 g EPA+DHA/d. Significant changes in inflammatory cytokine production by monocytes are decreases in their production in all instances. Overall, these studies fail to reveal strong dose–response effects of EPA+DHA on the outcomes measured and suggest that healthy subjects are relatively insensitive to immunomodulation with long-chain n-3 PUFA, even at intake levels that substantially raise their concentrations in phospholipids of immune cells. In patients with inflammatory conditions cytokine concentrations or production are influenced by EPA+DHA supplementation in a relatively large number of studies. Some of these studies suggest that local effects at the site of inflammation might be more pronounced than systemic effects and disease-related markers are more sensitive to the immunomodulatory effects, indicating that the presence of inflamed tissue or ‘sensitised’ immune cells in inflammatory disorders might increase sensitivity to the immunomodulatory effects of long-chain n-3 PUFA. In a substantial number of these studies clinical benefits related to the inflammatory state of the condition have been observed in the absence of significant effects on immune markers of inflammation. This finding suggests that condition-specific clinical end points might be more sensitive markers of modulation by EPA+DHA than cytokines. In general, the direction of immunomodulation in healthy subjects (if any) and in inflammatory conditions is the same, which indicates that studies in healthy subjects are a useful tool to describe the general principles of immunomodulation by n-3 PUFA. However, the extent of the effect might be very different in inflammatory conditions, indicating that studies in healthy subjects are not particularly suitable for establishing dose levels for specific applications in inflammatory conditions. The reviewed studies provide no indications that the immunomodulatory effects of long-chain n-3 PUFA impair immune function or infectious disease resistance. In contrast, in some conditions the immunomodulatory effects of EPA+DHA might improve immune function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Markers in COPD
Matsuyama, W., Mitsuyama, H., Watanabe, M., Oonakahara, K.-I., Higashimoto, I., Osame, M., & Arimura, K. (2005) · Chest · doi:10.1378/chest.128.6.3817 · Cited by 108
RetractedLee, T. H., Hoover, R. L., Williams, J. D., Sperling, R. I., Ravalese, J., Spur, B. W., Robinson, D. R., Corey, E. J., Lewis, R. A., & Austen, K. F. (1985) · New England Journal of Medicine · doi:10.1056/nejm198505093121903 · Cited by 1,333
Consumption of Fish and n-3 Fatty Acids and Risk of Incident Alzheimer Disease
Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Wilson, R. S., Aggarwal, N., & Schneider, J. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.940 · Cited by 1,135
Hong, S., Gronert, K., Devchand, P. R., Moussignac, R.-L., & Serhan, C. N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300218200 · Cited by 1,000
Conversion of α -linolenic acid to longer-chain polyunsaturated fatty acids in human adults
Burdge, G. C., & Calder, P. C. (2005) · Reproduction Nutrition Development · doi:10.1051/rnd:2005047 · Cited by 939
Self-citationFish consumption and the 30-year risk of fatal myocardial infarction
Daviglus, M. L., Stamler, J., Orencia, A. J., Dyer, A. R., Liu, K., Greenland, P., Walsh, M. K., Morris, D., & Shekelle, R. B. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704103361502 · Cited by 902
Marcheselli, V. L., Hong, S., Lukiw, W. J., Tian, X. H., Gronert, K., Musto, A., Hardy, M., Gimenez, J. M., Chiang, N., Serhan, C. N., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305841200 · Cited by 802
Mukherjee, P. K., Marcheselli, V. L., Serhan, C. N., & Bazan, N. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402531101 · Cited by 753 · cited 2×
“…mediators D-series resolvins, docosatrienes and neuroprotectins, also produced by cyclooxygenase-2 and lipoxygenase under some conditions, have been identified that also appear to be antiinflammatory and inflammation resolving (Hong et al. 2003; Marcheselli et al. 2003; Mukherjee et al. 2004).”
Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease
Sharon, P., & Stenson, W. F. (1984) · Gastroenterology · doi:10.1016/s0016-5085(84)80015-3 · Cited by 738
Mori, T. A., Woodman, R. J., Burke, V., Puddey, I. B., Croft, K. D., & Beilin, L. J. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(03)00407-6 · Cited by 322
Cited by
Wall, R., Ross, R. P., Fitzgerald, G. F., & Stanton, C. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00287.x · Cited by 1,101
Health Implications of High Dietary Omega-6 Polyunsaturated Fatty Acids
Patterson, E., Wall, R., Fitzgerald, G. F., Ross, R. P., & Stanton, C. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/539426 · Cited by 883
Inflammation: Depression Fans the Flames and Feasts on the Heat
Kiecolt-Glaser, J. K., Derry, H. M., & Fagundes, C. P. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15020152 · Cited by 844
Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids
Adkins, Y., & Kelley, D. S. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.12.004 · Cited by 557
Immunomodulation by omega-3 fatty acids
Calder, P. C. (2007) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2007.10.015 · Cited by 402
Self-citation
Metadata
- Authors
- Sijben, J. W. C., & Calder, P. C.
- Venue
- Proceedings of the Nutrition Society
- Publisher
- Cambridge University Press (CUP)
- Published
- 2007-04-30
- Volume
- 66
- Issue
- 2
- Pages
- 237-259
- ISSN
- 0029-6651 (ISSN-L)
- 1475-2719
- OpenAlex
- W2090418019
- Cited by
- 249
- References
- 18
- FWCI
- 16.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease. https://app.cochat.ai/papers/10.1017/s0029665107005472
- The paper
- Sijben, J. W. C., & Calder, P. C. (2007). Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease. Proceedings of the Nutrition Society. https://doi.org/10.1017/s0029665107005472
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.